Comparative Pharmacology
Head-to-head clinical analysis: AIRDUO DIGIHALER versus AIRSUPRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRDUO DIGIHALER versus AIRSUPRA.
AIRDUO DIGIHALER vs AIRSUPRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by increasing cyclic AMP. Fluticasone propionate is a corticosteroid with anti-inflammatory activity that inhibits inflammatory mediators and cells.
AIRSUPRA is a fixed-dose combination of albuterol (a short-acting beta2-agonist) and budesonide (an inhaled corticosteroid). Albuterol relaxes bronchial smooth muscle via beta2-adrenergic receptor activation, increasing cAMP and causing bronchodilation. Budesonide reduces airway inflammation by binding to glucocorticoid receptors, modulating gene transcription to suppress inflammatory mediators.
Two inhalations (umeclidinium 62.5 mcg and vilanterol 25 mcg per inhalation) orally once daily.
2 inhalations (albuterol 180 mcg / budesonide 160 mcg) orally inhaled twice daily (morning and evening), maximum 2 inhalations twice daily.
None Documented
None Documented
Fluticasone furoate: terminal elimination half-life is approximately 24 hours. Vilanterol: terminal elimination half-life is approximately 11 hours. The long half-life of fluticasone furoate supports once-daily dosing, while vilanterol's half-life allows for sustained bronchodilation over 24 hours.
Budesonide: 2-3 hours; formoterol: 10-14 hours; clinical context: steady state achieved within days for both
Fluticasone furoate and vilanterol are primarily eliminated via biliary/fecal routes. For fluticasone furoate, approximately 90% of an oral dose is excreted in feces as parent drug and metabolites, with <1% in urine. Vilanterol is predominantly excreted via feces (∼70%) as metabolites, with ∼20% in urine.
Budesonide: ~60% renal as metabolites, ~40% fecal; formoterol: ~60% renal, ~40% fecal
Category C
Category C
Inhaled Corticosteroid/LABA Combination
Inhaled Corticosteroid/SABA Combination